The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of topical heparin as treatment for patients (pts) with hand-foot syndrome (HFS) induced by capecitabine (CAP).
A. A. Rodriguez Garzotto A
No relevant relationships to disclose
L. C. Iglesias Docampo
No relevant relationships to disclose
C. Gravalos Castro
No relevant relationships to disclose
J. A. Lopez-Martin
No relevant relationships to disclose
T. Agullo Ortuno
No relevant relationships to disclose
V. Diaz Garcia
No relevant relationships to disclose
B. Homet
No relevant relationships to disclose
E. M. Ciruelos Gil
No relevant relationships to disclose
L. Manso
No relevant relationships to disclose
C. Mendiola
No relevant relationships to disclose
C. Gomez-Martin
No relevant relationships to disclose
R. Hitt
No relevant relationships to disclose
A. Gomez Camara
No relevant relationships to disclose
H. Cortes-Funes
No relevant relationships to disclose